U.S. market Closed. Opens in 12 hours 21 minutes

BCDAW | BioCardia, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for BCDAW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is on medium level and Health is frighteningly weak.

Valuation (5%)

Company Industry
P/E Ratio (TTM) -530.73 -23.05
PEG Ratio (TTM) -22.78 15.47
P/S Ratio (TTM) 19.80 49.46
P/B Ratio (TTM) -2,316.42 18.87
P/FCF Ratio (TTM) -1.19 -3.27
Price to 5YR AVG Earnings Ratio 0.00 -3.55
Price to 5YR AVG FCF Ratio 0.00 -9.37

Profitability (50%)

Company Industry
ROA (TTM) -296.16% -5.14%
ROE (TTM) 526.79% 16.69%
Net Profit Margin (TTM) -1,999.77% -1,583.93%
ROIC 5YR AVG 1,006.37% 15.15%

Growth (55%)

4QTR AVG 3YR AVG 5YR AVG
EPS 22.22% -339.49% -197.96%
Revenue 215.60% 178.01% 100.50%
Net Income 15.58% 2.60% 3.26%
Cash Flow 19.58% -0.02% 0.73%

Health (11%)

Company Industry
Current Ratio (TTM) 0.39 6.13
Quick Ratio (TTM) 0.39 5.85
D/E Ratio (TTM) -0.58 -15.81
Interest Coverage (TTM) -956.22 -1.57
Piotroski F-Score 4 5
Altman Z-Score N/A 14.12
LTL to 5YR AVG FCF -0.09 0.17
Shares Outstanding Growth 5YR AVG 15.91% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙